J Roberts

Happy to share a recent publication to kick off bleeding disorders awareness month! mdpi.com/2077-0383/15/4…

In a recent interview, @JonRob08 of @BloodExpertsIL discusses the findings of a study evaluating joint health status & bleeding phenotype in patients with severe & non-severe #hemophilia A or B using musculoskeletal ultrasound and other clinical tools.🩸 Watch here: 👉 ow.ly/YRzs50XLmKr #Hematology #ASH25

Interesting news and was really only a matter of time. Companies should listen to patients, and each individual weigh risks/benefits of all evolving hemophilia therapies. Sometimes patience is the wise approach. #hemophilia #genetherapy reuters.com/business/healt…

@Brianhemophilia @WHO @wfhemophilia Strong work!!! Patients around the world will benefit from this life-saving endeavor! ❤️🙌🏽 🩸

Celebrating the @WHO Essential Medicines List 2025 Update today which removes unsafe products and adds safe products thanks to the team @wfhemophilia

@BloodExpertsIL @nbd_foundation @isth @ASH_hematology @wfhemophilia @HTRStoday @THSNA_Societies @VwdConnect @UICOMPeoria @hemophiliafed

@BloodExpertsIL @nbd_foundation @isth @ASH_hematology @wfhemophilia @HTRStoday @THSNA_Societies @VwdConnect

Happy to share our study of recombinant VWF real-world treatment patterns and outcomes at 11 centers in the U.S. We demonstrate that routine rVWF prophylaxis reduced bleed rate and healthcare resource utilization compared to prior VWD treatments. #VWD #VWF tandfonline.com/doi/full/10.10…

@BloodExpertsIL @UICOMPeoria @VersitiResearch @Versiti @nbd_foundation @BloodAdvances @ASH_hematology

@BloodExpertsIL @UICOMPeoria @VersitiResearch @Versiti @nbd_foundation

Proud to work with esteemed colleagues to improve future research priorities. The patient voice, through lived experience experts, must be incorporated into cutting-edge research programs from start to finish. ashpublications.org/bloodadvances/…

@docrishabhsingh has a bright future and will be a phenomenal classical hematologist 👊🏽🙏🏽 congrats 🙌🏽 👏🏽

Honored to receive the Mary Draeger Schultz scholarship 2024 @OSFHealthCare! Grateful for the opportunity to promote #QI and #PatientSafety in healthcare, and for the incredible support from @UICOMPeoria @UicompP

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. onlinelibrary.wiley.com/doi/abs/10.111… This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.

Come say Hi! 🍷 Poster number: 5014 x.com/docrishabhsing…

A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3

Here is our just published review in #Blood focusing on how new biological insights into #FVIII are setting the stage for new #hemophilia therapies. #hemesky #medsky authors.elsevier.com/a/1k8Qn1UYwnF7k

@AaronGoodman33 Staying

@nbd_foundation @BloodExpertsIL

With 70% of bleeding events linked to identified or suspected causes, this study highlights the pressing need for better strategies, including long-term VWD factor (VWF) prophylaxis, to reduce hospitalizations and improve quality of life. Read More: bit.ly/3UWiu6Z

Centessa have discontinued development of their rebalancing agent, Serpin PC despite encouraging Phase 2 PREScent clinical trial results Decision due to competition from marstacimab and possibly concizumab. This leaves these 2 plus Fitusiran in trials or licenced @ProfMakris